# Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants

> **NCT04382586** · PHASE2 · COMPLETED · sponsor: **BeiGene** · enrollment: 63 (actual)

## Conditions studied

- COVID-19 Pulmonary Complications
- COVID-19

## Interventions

- **DRUG:** Zanubrutinib
- **DRUG:** Supportive Care
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04382586
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-06
- **Primary completion:** 2021-02-01
- **Final completion:** 2021-02-01
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2024-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04382586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04382586, "Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04382586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*